Reich Kristian 4

What Happened

• Kristian Reich, Chief Scientific Officer of MoonLake Immunotherapeutics (MLTX), sold a total of 52,448 ordinary shares in open-market transactions on July 21–22, 2026. The transactions consisted of 50,000 shares at an average reported price of $20.02 (≈ $1,001,000) and 2,448 shares at $20.00 ($48,960), for a combined proceeds of approximately $1,049,960. These were sales (not purchases), often viewed as routine disposition rather than a direct bullish signal.

Key Details

• Transaction dates and prices: July 21, 2026 — 50,000 shares at a reported weighted average price of $20.02 (sales executed across prices $20.00–$20.06); July 22, 2026 — 2,448 shares at $20.00.
• Total proceeds: ≈ $1,049,960.
• Plan/footnotes: The sales were executed pursuant to a Rule 10b5-1 trading plan adopted March 10, 2026. The $20.02 figure is a weighted average; the filing notes individual sale prices ranged $20.00–$20.06 and that detailed breakdowns can be provided to the SEC upon request.
• Ownership note: The filing discloses that JeruCON Beratungsgesellschaft mbH owns certain ordinary shares which Dr. Reich may be deemed to indirectly beneficially own (per footnote).
• Filing timeliness: Form 4 was filed July 23, 2026, appearing to be timely (filed within the usual two-business-day window required for Section 16 reporting).

Context

• Because these sales were made under a pre-established 10b5-1 plan, they were likely pre-planned dispositions rather than ad hoc insider trades; 10b5-1 plans are commonly used to schedule sales in advance. This is a sale transaction — purchases generally receive more attention as potential bullish signals.